Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis.

Cost effectiveness and resource allocation : C/E2026PMID: 41862906

Authors

Njei, Basile; Al-Ajlouni, Yazan A; Tanih, Dam Nsoh; Kanmounye, Ulrick Sidney; Boateng, Sarpong; Halwani, Khaled W; Nguefang, Guy Loic; Lim, Joseph

Cost-effectiveness analysisFibrosisGlucagon-like peptide 1 receptor agonistsNon alcoholic fatty liverThyroid hormone receptors beta